Camurus AB (publ) (CAMRF)
USD 59.98
(0.01%)
USD 59.98
(0.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 525.9 Million SEK | 630.87% |
| 2022 | 71.95 Million SEK | 165.07% |
| 2021 | -110.57 Million SEK | 46.12% |
| 2020 | -205.23 Million SEK | 42.99% |
| 2019 | -360.02 Million SEK | -25.35% |
| 2018 | -287.21 Million SEK | -17.94% |
| 2017 | -243.52 Million SEK | -137.7% |
| 2016 | -102.45 Million SEK | 49.8% |
| 2015 | -204.1 Million SEK | -427.51% |
| 2014 | 62.31 Million SEK | -51.05% |
| 2013 | 127.31 Million SEK | 578.62% |
| 2012 | 18.76 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 84.84 Million SEK | 5.01% |
| 2024 Q1 | 78.66 Million SEK | 375.63% |
| 2023 Q3 | 104.04 Million SEK | -72.33% |
| 2023 FY | 525.9 Million SEK | 630.87% |
| 2023 Q4 | -28.53 Million SEK | -127.43% |
| 2023 Q2 | 376.06 Million SEK | 405.9% |
| 2023 Q1 | 74.33 Million SEK | 293.74% |
| 2022 Q1 | 4.79 Million SEK | 126.4% |
| 2022 FY | 71.95 Million SEK | 165.07% |
| 2022 Q3 | 41.37 Million SEK | 498.28% |
| 2022 Q4 | 18.87 Million SEK | -54.37% |
| 2022 Q2 | 6.91 Million SEK | 44.33% |
| 2021 Q3 | -6.3 Million SEK | 89.45% |
| 2021 Q4 | -18.15 Million SEK | -187.87% |
| 2021 FY | -110.57 Million SEK | 46.12% |
| 2021 Q1 | -26.33 Million SEK | 67.73% |
| 2021 Q2 | -59.78 Million SEK | -127.04% |
| 2020 Q1 | -76.92 Million SEK | 12.99% |
| 2020 FY | -205.23 Million SEK | 42.99% |
| 2020 Q4 | -81.59 Million SEK | -248.81% |
| 2020 Q3 | -23.39 Million SEK | -0.3% |
| 2020 Q2 | -23.32 Million SEK | 69.68% |
| 2019 Q4 | -88.41 Million SEK | -14.25% |
| 2019 Q1 | -84.43 Million SEK | 18.18% |
| 2019 Q2 | -109.8 Million SEK | -30.05% |
| 2019 Q3 | -77.38 Million SEK | 29.53% |
| 2019 FY | -360.02 Million SEK | -25.35% |
| 2018 Q2 | -81.15 Million SEK | -74.8% |
| 2018 FY | -287.21 Million SEK | -17.94% |
| 2018 Q4 | -103.18 Million SEK | -82.82% |
| 2018 Q3 | -56.44 Million SEK | 30.45% |
| 2018 Q1 | -46.42 Million SEK | 29.73% |
| 2017 FY | -243.52 Million SEK | -137.7% |
| 2017 Q3 | -67.13 Million SEK | -14.33% |
| 2017 Q4 | -66.07 Million SEK | 1.58% |
| 2017 Q1 | -51.58 Million SEK | -46.82% |
| 2017 Q2 | -58.72 Million SEK | -13.83% |
| 2016 Q1 | -24.85 Million SEK | 38.5% |
| 2016 FY | -102.45 Million SEK | 49.8% |
| 2016 Q3 | -16.57 Million SEK | 35.95% |
| 2016 Q4 | -35.13 Million SEK | -111.96% |
| 2016 Q2 | -25.88 Million SEK | -4.12% |
| 2015 Q2 | -147.64 Million SEK | -1226.55% |
| 2015 Q1 | 13.1 Million SEK | -86.43% |
| 2015 Q3 | -29.14 Million SEK | 80.26% |
| 2015 Q4 | -40.41 Million SEK | -38.65% |
| 2015 FY | -204.1 Million SEK | -427.51% |
| 2014 Q4 | 96.6 Million SEK | 5087.4% |
| 2014 Q3 | -1.93 Million SEK | 0.0% |
| 2014 FY | 62.31 Million SEK | -51.05% |
| 2013 FY | 127.31 Million SEK | 578.62% |
| 2012 FY | 18.76 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | 81802.935% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 41971.258% |
| Skye Bioscience, Inc. | -13.67 Million USD | 3946.626% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -542.506% |
| Nascent Biotech, Inc. | -2.22 Million USD | 23684.374% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 3413.873% |
| BioStem Technologies, Inc. | -7.77 Million USD | 6860.575% |
| CSL Limited | 3.7 Billion USD | 85.794% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 3046.731% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 10525.31% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 76656.227% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 1047.436% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 126677.517% |
| Rebus Holdings, Inc. | -664 Thousand USD | 79302.259% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 39480.769% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 135095.765% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 832.598% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -10600.371% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 201036.476% |
| SQZ Biotechnologies Company | -75.82 Million USD | 793.575% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 18549.455% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 34337.384% |
| Mesoblast Limited | -84.14 Million USD | 724.981% |
| Marizyme, Inc. | -34.08 Million USD | 1642.848% |
| Genus plc | 6.4 Million USD | -8117.234% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -5298.052% |
| Pharming Group N.V. | -4.87 Million USD | 10877.708% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 26574.128% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 56564.923% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 6398.24% |
| ContraFect Corporation | -56.88 Million USD | 1024.437% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 11646.315% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 37611.154% |
| IMV Inc. | -38.67 Million USD | 1459.924% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 19217.913% |
| MultiCell Technologies, Inc. | -722.81 USD | 72758224.542% |
| ONE Bio Corp. | 13.68 Million USD | -3743.885% |
| Accustem Sciences Inc. | -3.74 Million USD | 14137.485% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 991.512% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 108968.634% |
| Q BioMed Inc. | -3.44 Million USD | 15362.96% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -14756.017% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 20115.17% |
| Biomind Labs Inc. | -1 Million USD | 52190.079% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 1056.668% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 18226.773% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 8010.677% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 28308.081% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 1755919.311% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 27312.06% |
| GB Sciences, Inc. | -1.42 Million USD | 37122.152% |
| Alpha Cognition Inc. | -9.7 Million USD | 5518.552% |
| HST Global, Inc. | -140.9 Thousand USD | 373327.022% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 46850.84% |
| Halberd Corporation | -75.05 Thousand USD | 700836.842% |
| Enzolytics Inc. | -2.14 Million USD | 24574.265% |
| Agentix Corp. | -1.37 Million USD | 38437.941% |
| Resverlogix Corp. | -12.74 Million USD | 4225.053% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 16699.038% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 223.728% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 50473.851% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 18113.807% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 33398.593% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 15545.117% |
| AVAX Technologies, Inc. | 6.69 Million USD | -7757.649% |
| Zenith Capital Corp. | -8.94 Million USD | 5980.611% |
| Genscript Biotech Corporation | -415.79 Million USD | 226.483% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 3018887.67% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 21518.945% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 306731.923% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 26332.755% |
| Kadimastem Ltd | -3.04 Million USD | 17398.018% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 53542.548% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 289877.668% |
| LadRx Corporation | -3.82 Million USD | 13854.039% |
| Cell Source, Inc. | -4.32 Million USD | 12258.634% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 76656.227% |
| NovAccess Global Inc. | -2.46 Million USD | 21419.585% |
| Affymax, Inc. | -15.04 Million USD | 3595.301% |
| Itoco Inc. | -919.14 Thousand USD | 57316.855% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 12508.014% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 47097.587% |
| Mobile Lads Corp. | -554.55 Thousand USD | 94934.19% |
| CytoDyn Inc. | -18.05 Million USD | 3012.299% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 2089504.052% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 239062.095% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 93225.833% |
| SYBLEU INC | -149.18 Thousand USD | 352629.159% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 29054.314% |
| International Stem Cell Corporation | -663 Thousand USD | 79421.719% |
| Bioxytran, Inc. | -3.82 Million USD | 13866.564% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 999155.851% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 2585660.472% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 1550.127% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 32603.276% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 71570.234% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 17004.629% |
| Neutra Corp. | -229.48 Thousand USD | 229265.614% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 3098.478% |
| PureTech Health plc | -146.19 Million USD | 459.717% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 2547.071% |
| IXICO plc | -1.43 Million USD | 36697.286% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 5641.07% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 531.755% |
| CSL Limited | 3.81 Billion USD | 86.204% |
| Cellectis S.A. | -108.85 Million USD | 583.112% |